Grade: Pharmaceutical Grade

Factory Location: Xiamen, Fujian

Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East

Monthly Production Capacity: 1000kg

Packaging Information: 25kg/drum 1kg/bottle

Delivery Lead Time: 7 days after payment

Sample Provided: yes

Payment Terms: L/L

Product name	Apalutamide / ARN-509
CAS No.	956104-40-8
Molecular Formula	C21H15F4N5O2S
Molecular Weight	477.442
Quality Standard	99% up by HPLC
Appearance	White powder

 

COA of Apalutamide

 

ITEMS	SPECIFICATION	RESULT
Appearance	White powder	Conforms
Solubility	Soluble in water or 1% acetic acid at a concentration of ≥1mg/ml to give a clear, colorless solution	Conforms
Related Substance (by HPLC)	Total Impurities ≤ 1.0%	0.17%
	Single impurity ≤ 0.2%	0.02%
Loss on drying	≤ 0.5%	0.3%
Assay (by HPLC)	99.0～103.0%	99.8%%
Conclusion	It meets the enterprise standard.

 

Usage

 

Function of apalutamide

As a second-generation nonsteroidal androgen receptor inhibitory drug, apalutamide can prevent the fusion of androgen and receptors, and block the transfer of AR to the nucleus of cancer cells. In addition, apalutamide can also control androgen and promote the growth of cancer cells.

 

The safety and efficacy of apalutamide are based on a randomized clinical trial of 1,207 patients with non-metastatic, castration-resistant prostate cancer. Patients in the trial received apalutamide or placebo. All patients also received hormone therapy, either with a gonadotropin-releasing hormone (GnRH) analog, or with surgery to lower the amount of testosterone in the body (surgical castration). Median metastasis-free survival was 40.5 months for patients taking apalutamide, compared with 16.2 months for patients taking placebo. From the above experiments, we can see that the effect of apalutamide in the treatment of prostate cancer is very significant.